Payer Adoption Mind.Px offers clear payer value through potential savings on costly psoriasis biologics, aligning with the cost-management priorities of health plans and PBMs. The company already partnered with Liviniti and has New York State Department of Health approval for Mind.Px, signaling payer-ready deployment. Target opportunities include commercial plans, Medicaid/Medicare, and PBMs to integrate Mind.Px into formulary decisions and prior-authorization workflows.

Dermatology Reach The Mind.Px test is designed for dermatology patients, using a dermal biomarker patch and machine learning to guide biologic decisions. There is an immediate opportunity to expand within dermatology networks, academic medical centers, and specialty clinics treating psoriasis, psoriatic arthritis, and eczema. With the planned product pipeline, the platform could become a multi-indication solution that drives broader clinician adoption.

Regulatory Momentum Regulatory momentum from the NY approval demonstrates readiness for regulated commercialization and strengthens credibility with payers and providers. Mindera Health can prioritize multi-state expansion to accelerate market access and formulary inclusion. Pursue partnerships with regional health plans and hospital systems focused on value-based care to catalyze faster adoption.

Strategic Partnerships Existing partnerships with the National Psoriasis Foundation and a Pharmacy Benefit Manager signal readiness for collaboration and patient-centered programs. There is potential to co-develop with pharmaceutical companies developing psoriasis biologics or other dermatology biologics to de-risk expensive therapies. Leverage Dermal Intelligence data to support payer-focused outcomes research and to feed future product development.

Growth Signals Mindera Health reports revenue in the tens of millions and has attracted investor interest, including convertible note financing and leadership hires. This indicates capacity to scale sales, clinical pilots, and payer engagements. Leverage this momentum to pursue enterprise dermatology groups, health systems, and payer partnerships for larger pilots and long-term contracts.